Evidence map›Paper›PMID 41534847›Full record

ArticleActa psychiatrica Scandinavica2026

Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan.

Masaki Fujiwara, Yuto Yamada, Taisuke Ishii, Tomone Watanabe, Maiko Fujimori, Naoki Nakaya, Toshihiko Kawamura, Koji Otsuki, Kunitoshi Shigeyasu, Taichi Shimazu and 3 more

Abstract readMulticenter Study
In one paragraph

Article in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masaki FujiwaraDepartment of Neuropsychiatry, Medical Development Field, Okayama University, Okayama, Japan.
Yuto YamadaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Taisuke IshiiDivision of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Tomone WatanabeDivision of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Maiko FujimoriDivision of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Naoki NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.ORCID 0000-0002-1467-161X
Toshihiko KawamuraDepartment of Medical Informatics, Shimane University Hospital, Izumo, Japan.
Koji OtsukiDepartment of Psychiatry, Faculty of Medicine, Shimane University, Izumo, Japan.ORCID 0000-0002-0980-3614
Kunitoshi ShigeyasuDepartment of Gastroenterological Surgery, Medical Development Field, Okayama University, Okayama, Japan.
Taichi ShimazuDivision of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Shiro HinotsuDepartment of Biostatistics and Data Management, Sapporo Medical University, Sapporo, Japan.
Yosuke UchitomiDepartment of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Masatoshi InagakiDepartment of Psychiatry, Faculty of Medicine, Shimane University, Izumo, Japan.ORCID 0000-0002-9822-8649

Funding

JSPS KAKENHI 21K17249JSPS KAKENHI JP23K09549Research for Promotion of Cancer Control Programs from the Japanese Ministry of Health, Labour and Welfare 23EA1031
6 · The paper itself

Abstract

introductionThis study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage-appropriate systemic therapy within a universal healthcare system.

methodIn this nationwide retrospective cohort study (2018-2021), we identified 248,966 colorectal cancer patients, including 2337 diagnosed with SSD, using linked cancer registry and insurance claims data in Japan. The presence of SSD was classified according to ICD-10 codes F20-29. We used multivariable logistic regression to compare the odds of receiving stage-appropriate adjuvant chemotherapy and systemic therapy, as well as the odds of receiving surgical or endoscopic treatments, between the two groups. The analysis adjusted for age, sex, clinical stage, and scores on the Charlson Comorbidity Index and Barthel Index.

resultsThe clinical stage distribution at diagnosis for colorectal cancer differed significantly between patients with SSD and those without psychiatric disorders (p < 0.001). After adjusting for clinical stage and other covariates, patients with SSD demonstrated significantly lower odds of receiving surgical or endoscopic treatment (adjusted odds ratio [aOR], 0.83; 95% CI, 0.73-0.94). The disparities were more pronounced for systemic therapy; patients with SSD had substantially lower odds of receiving adjuvant chemotherapy for stage III disease (aOR, 0.33; 95% CI, 0.26-0.41) and systemic therapy for stage IV disease (aOR, 0.23; 95% CI, 0.17-0.31).

conclusionPatients with SSD encounter substantial disparities in accessing standard colorectal cancer care, particularly systemic therapies. These findings highlight the urgent need for interventions to ensure equitable cancer treatment for this vulnerable population.

Indexed as

Colorectal NeoplasmsHealthcare DisparitiesSchizophreniaAdultAgedChemotherapy, AdjuvantFemaleHumansJapanMaleMiddle AgedNeoplasm StagingRegistriesRetrospective StudiesUndertreatmentcolorectal cancerhealthcare disparitiespsycho‐oncologyschizophrenia spectrum disorders

Identifiers

PMID41534847
PMCPMC12861577

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.